In conclusion, robot-assisted gastric surgery is now considered to be feasible in patients with Stage IA (T1N0) and Stage IB (T1N1, T2N0) early gastric cancer. The optimal treatment modalities have yet to be identified, however, and therefore clinical trials are called for. The authors believe that this new technology will markedly increase the survival rate of such patients all over the world in the near future, while also helping to significantly decrease the complication rates and hospital stay of the patients, which will thus result in a major beneficial socioeconomic impact.